CALIBRATE: Wk 54 Primary Analysis of Long-Acting Subcutaneous Lenacapavir in Treatment-Naive Patients

Source: Conference Coverage of CROI 2022: Clinical Impact of New HIV Data*
Download Slideset
February 13-16, 2022; Virtual
Two regimens featuring a subcutaneous lenacapavir backbone administered every 6 months conferred complete virologic suppression in 85% to 90% of patients at Week 54.
Format: Microsoft PowerPoint (.ppt)
File Size: 456 KB
Released: February 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Cepheid
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings